GlobeNewswire Inc.··NaBeam Therapeutics' BEAM-302 Shows Promise in Alpha-1 Deficiency, Eyes Pivotal Trial
Beam Therapeutics reports positive Phase 1/2 data for BEAM-302 base editing therapy in alpha-1 antitrypsin deficiency, advancing toward pivotal development in late 2026.
BEAMclinical trialgene therapy